Needham Downgrades Hims & Hers Stock (HIMS) on Fallout with Novo Nordisk. Wall Street Sees Legal Risks

Hims & Hers (HIMS) stock plummeted 35% after Novo Nordisk (NVO) terminated their partnership, accusing HIMS of illegally selling Wegovy copycats. This prompted widespread analyst downgrades, citing significant legal and regulatory risks, competitive disadvantage, and potential impacts on HIMS's compounded GLP-1 revenue, which some estimate comprises over 50% of its weight-loss segment. Analysts anticipate prolonged litigation and a continued overhang on the stock as the legality of HIMS's personalization practices is determined, leading Wall Street to maintain a largely sidelined consensus rating.

Analysis

Hims & Hers (HIMS) stock experienced a severe 35% decline following the termination of its partnership with Novo Nordisk (NVO), which accused HIMS of selling illegitimate copycats of its Wegovy drug. This event has triggered multiple analyst downgrades and a significant reassessment of the company's risk profile. The primary concern is the heightened probability of a protracted legal battle, which Truist Securities estimates could create an 18-24 month overhang on the stock. While the direct revenue loss from branded Wegovy is minimal—estimated by Bank of America at just 2% of GLP-1 orders—the core of the issue lies in HIMS's substantial compounded semaglutide business. Morgan Stanley estimates this segment comprises over 50% of the company's targeted $725 million in 2025 weight-loss revenue, a business now facing significant legal and regulatory jeopardy under section 503A. Furthermore, the fallout places HIMS at a competitive disadvantage against rivals who maintain legitimate partnerships with GLP-1 manufacturers like Eli Lilly and Novo Nordisk. Adding to these headwinds, Bank of America noted a potential slowdown in HIMS's core business, presenting a risk to consensus estimates for the second half of 2025 and 2026, independent of the GLP-1 controversy.

Key Decisions for Investors

• Investors should anticipate HIMS stock to remain range-bound and under pressure due to the significant overhang from potential litigation with Novo Nordisk, which could last up to 24 months.
• Monitor HIMS's compounded semaglutide revenue, as any adverse legal or regulatory ruling regarding its interpretation of section 503A poses a direct threat to what analysts estimate is over half of its projected 2025 weight-loss revenue.
• Look for evidence of deceleration in HIMS's core business, a risk flagged by Bank of America that could jeopardize future earnings estimates regardless of the outcome of the GLP-1 dispute.
• Re-evaluate HIMS's long-term competitive standing, as the loss of the Novo Nordisk partnership cedes a key advantage to competitors with established, legitimate access to branded GLP-1 drugs.